Dextroamphetamine
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Dextroamphetamine
- Pharmacist Assessment Report
- Dextroamphetamine: catecholamine-releasing CNS stimulant → faciodigitogenital syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Dextroamphetamine: catecholamine-releasing CNS stimulant → faciodigitogenital syndrome
One-Sentence Summary
Dextroamphetamine is a central nervous system stimulant that releases catecholamines and blocks their reuptake, and it is marketed in Canada. The TxGNN model predicts it may be useful for faciodigitogenital syndrome, but no clinical trials and no publications directly support this prediction. The prediction rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | faciodigitogenital syndrome |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Dextroamphetamine releases catecholamines and inhibits their reuptake (through TAAR1, VMAT2 and the dopamine transporter). Detailed mechanism-of-action data are not otherwise available in the data compiled for this report.
Faciodigitogenital syndrome (Aarskog-Scott syndrome, FGD1-related) can include ADHD-like behavioural features. A stimulant could in principle ease those symptoms. This is an inference only: it would be symptom management, not disease modification, and no study in the data compiled for this report tests it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02448327 | TEVA-DEXTROAMPHETAMINE SR | Not recorded | Not recorded |
| 02448319 | TEVA-DEXTROAMPHETAMINE SR | Not recorded | Not recorded |
| 01924516 | DEXEDRINE | Not recorded | Not recorded |
| 01924567 | DEXEDRINE SPANSULE | Not recorded | Not recorded |
| 01924559 | DEXEDRINE SPANSULE | Not recorded | Not recorded |
All six single-ingredient licences are valid; the table lists the first five.
Safety Considerations
- Drug Interactions: 62 interactions were recorded. Examples of major-level interactions are bupropion, dexfenfluramine, fenfluramine and sibutramine. Moderate-level examples include epinephrine, ephedrine, isometheptene, and several antacids and alkalinising agents (aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium oxide, potassium citrate).
- Conditions of concern: The data compiled for this report flag caution in hypertension, cardiovascular and cerebrovascular disease, epilepsy, bipolar and psychotic disorders, glaucoma, hyperthyroidism, anorexia nervosa and substance-related disorders. These are not taken from label text. Please confirm against the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score (0.9999) but no trials or literature on faciodigitogenital syndrome, so the evidence level is L5. Any plausible benefit is limited to treating ADHD-like symptoms, not the underlying disease.
To proceed, the following is needed:
- Case series or trials of stimulant use in FGD1-related (Aarskog-Scott) syndrome, particularly for behavioural symptoms
- Package insert warnings and contraindications from Health Canada
- Detailed mechanism-of-action data
- A cardiovascular and psychiatric safety assessment for this population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.